Which ICD‑10‑CM code should be used for a prostate‑specific antigen (PSA) screening test and for documenting an elevated PSA result?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10 Codes for PSA Testing

For PSA screening in asymptomatic men, use Z12.5 (Encounter for screening for malignant neoplasm of prostate), and for documenting an elevated PSA result, use R97.20 (Elevated prostate specific antigen [PSA]).

Screening Context (Asymptomatic Men)

When ordering PSA testing as part of prostate cancer screening in men without symptoms or known prostate disease:

  • Primary code: Z12.5 - This is the appropriate screening code for asymptomatic men undergoing PSA testing for early detection of prostate cancer 1

The NCCN guidelines emphasize that PSA is the best evidence-supported test for early detection of prostate cancer, with screening discussions recommended for men ages 45-75 years with baseline PSA ≥1 ng/mL 1.

Elevated PSA Result Documentation

When PSA results return elevated and you need to document this finding:

  • Use R97.20 (Elevated prostate specific antigen) - This abnormal finding code captures the elevated PSA result itself

Important thresholds to note:

  • Traditional biopsy threshold: PSA >4.0 ng/mL 2, 3
  • However, prostate cancer can occur at any PSA level, including <1.0 ng/mL 4
  • The level of PSA correlates with cancer risk - approximately 30-35% of men with PSA 4-10 ng/mL will have cancer on biopsy 1

Post-Treatment Monitoring Context

For men with known prostate cancer history being monitored:

  • After radical prostatectomy with rising PSA: Use the primary prostate cancer diagnosis code (typically C61) along with Z85.46 (Personal history of malignant neoplasm of prostate) if in remission, or continue using C61 if active disease
  • Biochemical recurrence is defined as: PSA ≥0.2 ng/mL confirmed on two successive assays after prostatectomy 5

Additional Relevant Codes

  • Z19.2 (Hormone resistant malignancy status/Castration-resistant prostate cancer) - Note that this code significantly underidentifies CRPC patients, capturing only about 27% of actual cases compared to comprehensive algorithms 6. Use this code when CRPC is explicitly documented, but recognize its limitations for research or quality improvement purposes.

Common Pitfalls to Avoid

  1. Don't use diagnostic codes for screening: Using C61 (malignant neoplasm of prostate) for screening PSA in asymptomatic men is incorrect and may cause insurance denials

  2. PSA is not cancer-specific: Only about 25% of men with PSA 4-10 ng/mL actually have cancer 1. The elevated PSA code (R97.20) documents the abnormal finding, not a cancer diagnosis

  3. Consider factors affecting PSA:

    • 5α-reductase inhibitors (finasteride, dutasteride) decrease PSA by approximately 50% 1
    • Infection, recent instrumentation, ejaculation, or trauma can elevate PSA 1
    • BPH commonly causes PSA elevation without cancer 3
  4. Age-specific considerations: For men >75 years, screening should be done cautiously and only in very healthy men with minimal comorbidity, as overdetection becomes a significant concern 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.